CLPT Expands Into Robotic System Supporting Cell and Gene Therapies
ClearPoint's new Robotic Neuro-Navigation System merges proven software with KUKA robotics to boost precision in cell and gene therapy delivery.
BRKR Shares Climb After Securing New Orders for Its NMR Systems
Bruker stock climbs after securing $10M in federally funded NMR orders from top U.S. research institutions.
Why Masimo ( MASI ) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is the Options Market Predicting a Spike in Masimo Stock?
Investors need to pay close attention to MASI stock based on the movements in the options market lately.
ILMN Stock Set to Benefit From the Launch of New BioInsight Division
Illumina launches BioInsight to harness multiomic data, accelerate drug discovery, and boost disease diagnosis.
ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves
AngioDynamics posts narrower-than-expected Q1 loss, 12% revenue growth and margin gains. it also raises FY26 sales outlook, sending shares higher.
HOLX Stock Gains on FDA & CE Approval for Automated Molecular GI Tests
Hologic's shares rise after receiving FDA clearance and CE mark for its rapid molecular GI assays on the Panther Fusion platform.
Here's How Much $100 Invested In Masimo 10 Years Ago Would Be Worth Today - Masimo ( NASDAQ:MASI )
Masimo ( NASDAQ: MASI ) has outperformed the market over the past 10 years by 1.12% on an annualized basis producing an average annual return of 13.99%. Currently, Masimo has a market capitalization of $7.72 billion.
IDEXX Laboratories Stock Rallies 52.9% YTD: What's Behind the Drive?
IDXX soars 52.9% YTD, fueled by strong CAG Diagnostics growth, global expansion and rising demand for software solutions.
Bio-Techne Stock Climbs on Advances in Spatial Biology Solutions
TECH shares rise as advances in RNAscope and COMET spotlight new roles in lymphoid malignancy diagnostics.
Growing Diagnostics Arm Supports ABT Stock, Macro Issues Ail
ABT gains momentum with strong FreeStyle Libre sales and Diagnostics growth but global macro headwinds weigh on performance.
Insulet Stock Surges 37.4% in 12 months: What's Driving the Rally?
PODD stock rallies 37.4% in a year, fueled by Omnipod 5 adoption, global launches and expanding reach in diabetes care.
Don't Overlook These 2 Highly Ranked Medical Stocks: COLL, MASI
Two medical sector stocks are standing out among the recent additions to the Zacks Rank #1 (Strong Buy) list in Collegium Pharmaceutical (COLL) and Masimo Corporation (MASI).
National Vision Gains 166.5% in a Year: What's Driving the Rally?
EYE's 166.5% stock surge in a year is fueled by transformation efforts, partnerships, and strong growth in its Owned & Host segment.
Masimo Completes Divestment of Consumer Audio Business to HARMAN
MASI completes sale of Sound United to HARMAN, sharpening focus on core healthcare, boosting margins, and funding buybacks.
Phibro Animal Health Stock Surges 82.1% YTD: What's Fueling It?
PAHC rallies 82% YTD with booming vaccines, MFAs and global expansion fueling investor confidence.
Medtronic Receives FDA Nod for Altaviva Device: Stock to Gain?
MDT gains FDA approval for its Altaviva device, a minimally invasive bladder control therapy with long-lasting benefits.
Is it a Prudent Move to Retain BSX Stock in Your Portfolio for Now?
Boston Scientific's acquisitions and WATCHMAN growth fuel optimism, but currency swings and macro pressures weigh on its outlook.
Reasons to Add Labcorp Stock to Your Portfolio Right Now
LH's biopharma lab growth and efficiency gains boost momentum, but currency and macro pressures weigh on its outlook.
Should You Hold STERIS Stock in Your Portfolio Right Now?
STE posts solid Healthcare and AST growth with strong liquidity but faces macroeconomic and currency headwinds.
Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now?
DGX posts strong gains from physician and hospital channels while advancing AI-powered solutions.
All You Need to Know About Masimo ( MASI ) Rating Upgrade to Strong Buy
Masimo (MASI) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Alcon sees growth from surgical innovation and vision care products, but faces macro pressures and fierce competition.
MASIMO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Masimo Corporation - MASI - Masimo ( NASDAQ:MASI )
NEW ORLEANS, Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ( "KSF" ) , announces that KSF has commenced an investigation into Masimo Corporation MASI.
Is it the Right Time to Retain Abbott Stock in Your Portfolio?
ABT's strong Nutrition, Diabetes Care and EPD growth fuel momentum, but macro and currency headwinds challenge its outlook.
Baxter Stock Slips Despite Latest Launch to Boost Patient Monitoring
BAX launches FDA-cleared Connex 360 monitor, aiming to boost frontline care and streamline patient monitoring.
Alcon's UNITY VCS Shows Superior Efficiency in Studies, Stock Up
ALC's UNITY VCS shows faster, more efficient cataract and vitreoretinal surgery results, lifting shares after study presentations.
Here's Why Masimo ( MASI ) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
LH Stock Rises on Acquisition of BioReference Health's Select Assets
Labcorp's $225M acquisition of BioReference Health select assets boosts its oncology diagnostics portfolio and expands patient access nationwide.
The New Olink Target 48 Neurodegeneration Panel May Boost TMO Stock
Thermo Fisher unveils the Olink Target 48 Neurodegeneration panel to accelerate biomarker research in neurodegenerative diseases.
Should You Continue to Hold Integra Stock in Your Portfolio Now?
IART shows strong demand in neurosurgery and Tissue Technologies but faces macro and liquidity challenges.
Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now?
Myriad Genetics expands oncology testing and launches new diagnostics, but inflation and rising competition weigh on its outlook.
QGEN Stock Gains From CE-IVDR Certification for QIAstat-Dx Portfolio
QIAGEN secures CE-IVDR certification for its full QIAstat-Dx portfolio, boosting its diagnostics arm and lifting shares.
Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs
EXAS introduces Cancerguard, a blood test that detects more than 50 cancers, sending shares up after its U.S. debut.
Should You Add IDEXX Stock to Your Portfolio Right Now?
IDXX shows strong CAG Diagnostics growth, cloud software momentum and global expansion but faces solvency and macro risks.
CRL Stock Rises Following New Strategic Oncology Collaborations
Charles River shares rise after new collaborations with PICI and CHLA, boosting its oncology and cell therapy pipeline momentum.
Here's Why You Should Add NVST Stock to Your Portfolio Right Now
Envista's global expansion, strategic acquisitions, and solid solvency boost growth outlook despite FX headwinds.
Should You Continue to Hold EXAS Stock in Your Portfolio?
Exact Sciences sees growth in Cologuard and Oncotype DX, but rising costs and tough competition weigh on EXAS shares.
Here's Why You Should Add PAHC Stock to Your Portfolio Right Now
Phibro Animal Health posts strong Animal Health sales growth, aided by a Zoetis acquisition, while Mineral Nutrition and Performance Products rebound.
ILMN Stock to Gain From the Launch of Illumina Protein Prep Assay
The Illumina Protein Prep rollout boosts multiomics, strengthens disease insights and supports ILMN stock momentum.
How Is The Market Feeling About Masimo? - Masimo ( NASDAQ:MASI )
Masimo's MASI short percent of float has risen 25.65% since its last report. The company recently reported that it has 4.11 million shares sold short, which is 11.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.83 days to cover their ...
Should You Hold Onto Globus Medical Stock in Your Portfolio for Now?
GMED rides strong musculoskeletal demand and new launches, but faces currency headwinds and fierce competition.
Is it the Right Time to Add CRL Stock to Your Portfolio Now?
Charles River's DSA growth, acquisitions and collaborations support momentum, but forex and macro headwinds weigh on its outlook.
New Strong Buy Stocks for September 4th
LRN, RL, ATRO, MASI and BYD have been added to the Zacks Rank #1 (Strong Buy) List on September 4, 2025.
QIAGEN Stock May Benefit From the US Clearance of QIAstat-Dx Rise
QGEN announces the launch of FDA-cleared QIAstat-Dx Rise, which may boost U.S. diagnostic access and testing capacity worldwide.
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
RMD's Mask and Device sales fuel growth, but macro headwinds and fierce competition continue to challenge its performance.
Charles River Stock May Benefit From Joining EASYGEN Consortium
CRL joins EASYGEN to speed CAR-T therapy delivery, which may boost patient access and investor sentiment.
Is it Apt to Hold Bio-Rad Stock in Your Portfolio Now?
BIO's strong ddPCR growth and solid diagnostics demand support its stock despite market pressures and stiff competition.
Bet on 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Post Holdings, Service Corporation International, TAL Education Group, Masimo and Okta.
Here is Why Growth Investors Should Buy Masimo ( MASI ) Now
Masimo (MASI) could produce exceptional returns because of its solid growth attributes.
